NASDAQ RESUMED AT 09:40 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
GT Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Gt Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: GT Biopharma Announces First Patient Dosed In Phase 1 Trial Of GTB-5550, A B7-H3-Targeted Natural Killer (NK) Cell Engager For Solid Tumors
U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
Brief: GT Biopharma Gets FDA IND Clearance For GTB-5550 TRiKE, B7-H3-Targeted NK Engager For B7-H3+ Solid Tumors
GT Biopharma surges as FDA clears human trial for new cancer drug
Brief: GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
Brief: GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
Brief: GT Biopharma Provides Enrollment Update On GTB-3650 Phase 1 Trial In Patients With Relapsed Or Refractory (R/R)CD33 Expressing Hematologic Malignancies
GT Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary